FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.

被引：0
|
作者：
Sridhar, Srikala S.
Power, Nicholas
Breau, Rodney H.
Cheng, Susanna Y.
Pond, Gregory Russell
Chung, Peter W. M.
Metser, Ur
Levine, Mark Norman
Mukherjee, Som D.
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] London Hlth Sci Ctr, London, ON, Canada
[3] Ottawa Hosp, Ottawa, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[5] McMaster Univ, Ontario Clin Oncol Grp, Hamilton, ON, Canada
[6] Univ Hlth Network, Radiat Med Program, Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Princess Margaret Hosp, Toronto, ON, Canada
[8] Ontario Clin Oncol Grp, Hamilton, ON, Canada
[9] McMaster Univ, Dept Oncol, Juravinski Canc Ctr, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
460
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Defining molecular and laboratory predictive biomarkers of response to cisplatin-based neoadjuvant chemotherapy (NC) in muscle-invasive bladder cancer (MIBC) - preliminary results and future plans
    Leibowitz-Amit, Raya
    Seah, Jo-An
    Berger, Raanan
    Sridhar, Srikala S.
    CANCER RESEARCH, 2014, 74 (19)
  • [22] A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer
    Agarwal, Archana
    Sonpavde, Guru
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 : S254 - S256
  • [23] Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer
    Einerhand, Sarah M. H.
    Voskuilen, Charlotte S.
    van de Putte, Elies E. Fransen
    Donswijk, Maarten L.
    Bruining, Annemarie
    van Der Heijden, Michiel S.
    Mertens, Laura S.
    Hendricksen, Kees
    Vegt, Erik
    van Rhijn, Bas W. G.
    BLADDER CANCER, 2023, 9 (01) : 49 - 57
  • [24] Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy
    Fitoussi, Olivier
    Roche, Jean Baptiste
    Riviere, Julien
    Wallerand, Herve
    Poulain, Jean Eude
    Gordien, Pierre
    Galland, Sigolene
    Henriques, Benedicte
    Dupin, Camille
    Vincent, Muriel
    Kuratle, Thomas
    Saffarini, Mo
    Ramos-Pascual, Sonia
    UROLOGIA INTERNATIONALIS, 2023, 107 (03) : 239 - 245
  • [25] Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).
    Khaki, Ali Raza
    Shan, Yong
    Nelson, Richard
    Kaul, Sapna
    Gore, John L.
    Grivas, Petros
    Williams, Stephen B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function
    Koshkin, Vadim S.
    Barata, Pedro C.
    Rybicki, Lisa A.
    Zahoor, Haris
    Almassi, Nima
    Redden, Alicia M.
    Fergany, Amr F.
    Kaouk, Jihad
    Haber, Georges-Pascal
    Stephenson, Andrew J.
    Ornstein, Moshe C.
    Gilligan, Timothy
    Garcia, Jorge A.
    Rini, Brian, I
    Grivas, Petros
    CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : E879 - E892
  • [27] Association of Medicaid expansion with racial disparities in timely neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC).
    Jiang, Changchuan
    Perimbeti, Stuthi
    Deng, Lei
    Jatwani, Karan
    Roy, Arya
    Chatta, Gurkamal S.
    George, Saby
    Gopalakrishnan, Dharmesh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [28] The impact of neoadjuvant chemotherapy (NAC) on conditional survival (CS) among patients with muscle-invasive bladder cancer (MIBC).
    Waingankar, Nikhil
    Jia, Rachel
    Ferket, Bart
    Audenet, Francois
    Mehrazin, Reza
    Sfakianos, John
    Mazumdar, Madhu
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Assessment of sarcopenia as predictor of response and outcome after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC).
    Grivas, Petros
    Zargar, Homi
    Ercole, Cesar Emilio
    Kovac, Evan
    Remer, Erick M.
    Karim, Wadih
    Emamekhoo, Hamid
    Stephenson, Andrew J.
    Fergany, Amr Farouk
    Gong, Michael C.
    Campbell, Steven C.
    Berglund, Ryan Kent
    Dreicer, Robert
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Frequency and clinical implications of pathologic complete response (pCR) at cystectomy for muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC)
    Galsky, Matt D.
    Stensland, Kristian
    Sfakianos, John
    McBride, Russell Bailey
    Mehrazin, Reza
    Tsao, Che-Kai
    Boffetta, Paolo
    Oh, William K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345